

## COVID-19 Vaccine Information Brief

October 17, 2022

### IMPORTANT/NEW COVID-19 Vaccine Information

- COVID-19 Vaccine Allocation Schedule
- FDA Authorizes Moderna and Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster
- ACIP Meeting Update
- Pediatric Booster Availability
- Monovalent Boosters No Longer Authorized
- Pediatric Bivalent Booster Training
- Mini-Webinars Regarding Bivalent COVID-19 Boosters
- COVID-19 Vaccine Resources
- COVID-19 Vaccine Access and Wastage Guidance
- Coadministration of COVID-19 Vaccine With Influenza and Other Vaccines
- V-Safe After Vaccination Health Checker

### COVID-19 VACCINE ALLOCATION SCHEDULE

The CDC is transitioning to a monthly COVID-19 vaccine allocation for monovalent COVID-19 vaccine. The following information outlines the vaccine allocation schedule for the remainder of 2022.

As much as possible, bivalent vaccine allocations/surveys will be incorporated into the monthly vaccine ordering schedule. **If necessary, separate bivalent vaccine allocation will occur as allocations are received from the federal government.**

- October 24, 2022- Bivalent only survey
- November 7, 2022
- December 5, 2022
- January 3, 2023

### FDA AUTHORIZES MODERNA AND PFIZER-BIONTECH BIVALENT COVID-19 VACCINES FOR USE AS A BOOSTER

The U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna COVID-19 Vaccine, Bivalent and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent to authorize their use as a single booster dose in younger age groups.

- The Moderna COVID-19 Vaccine, Bivalent is authorized for use as a single booster dose in individuals 6 years of age and older.

- The Pfizer-BioNTech COVID-19 Vaccine, Bivalent is authorized for use as a single booster dose in **individuals 5 years of age and older.**

The full FDA release is available at:

[Coronavirus \(COVID-19\) Update: FDA Authorizes Moderna and Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose in Younger Age Groups | FDA](#)

---

### **ACIP MEETING UPDATE**

An ACIP meeting is not necessary for updated (bivalent) COVID-19 boosters for children ages 5 through 11 years. ACIP has already reviewed the relevant data—and in order to avert delays in providing updated boosters for children ages 5 through 11 years—CDC is recommending the use of these products and helping make them available to children ages 5 through 11 years across the United States.

At the [September 1, 2022 ACIP meeting](#), ACIP had the opportunity to review and discuss data about updated (bivalent) COVID-19 boosters for all age groups for which monovalent COVID-19 boosters had been previously recommended. These groups included people ages 12 years and older, as well as children ages 5 through 11 years. In order for ACIP to vote to recommend any specific vaccine product, however, FDA needs to have issued an emergency use authorization (EUA) for that product. EUAs were available on September 1, 2022 for updated (bivalent) boosters for people ages 12 years and older, but not for children ages 5 through 11. This was due to ongoing work in manufacturing and production of products for the younger age group. Manufacturing and production are complete and EUAs are now available for updated COVID-19 boosters for children ages 5 through 11 years.

---


### **PEDIATRIC BOOSTER AVAILABILITY**

#### **Moderna**

Moderna pediatric bivalent boosters are approved using a half-dose of the bivalent vaccine currently being administered to adults. The letter to healthcare providers with important prescribing information is available at [Moderna DHCP Letter Bivalent 10122022 \(fda.gov\)](#).

Because this vaccine is currently being administered to adults, inventory already exists in the field for use with children. Administration to pediatric patients can begin immediately using existing Moderna inventory. Please review the DHCP link above to avoid administration errors in children.

*Moderna Bivalent COVID-19 Vaccine Label (adult and pediatric)*



## Pfizer

**Pre-orders of Pfizer pediatric bivalent vaccines are expected to begin delivery on Monday, October 17.**

Providers may begin scheduling appointments immediately in anticipation of these deliveries.

*Pfizer Pediatric COVID-19 Labels (monovalent and bivalent)*



## MONOVALENT BOOSTERS NO LONGER AUTHORIZED

Monovalent mRNA COVID-19 vaccines are no longer authorized as booster doses for individuals 5 years of age and older.

Individuals are [up to date](#) with COVID 19 vaccines if they have completed a COVID-19 vaccine primary series and received the most recent booster dose recommended by CDC. Anyone over the age of 5 are currently recommended to receive a bivalent booster.

## PEDIATRIC BIVALENT BOOSTER TRAINING

**Pfizer:** Offers virtual training for providers of Pfizer-BioNTech COVID-19 vaccine primary series and bivalent Pfizer-BioNTech COVID-19 boosters for people 5 years of age and older. To access dates and links for upcoming training sessions, [visit the Pfizer website](#).

**Moderna:** Providing daily opportunities for Q&A through October 28, 2022. Register to attend any of these sessions at the following link: [Moderna Office Hours](#).

## MINI-WEBINARS REGARDING BIVALENT COVID-19 BOOSTERS

CDC is offering a series of brief (15-20 minute) webinars addressing topics around COVID-19 vaccination. These interactive, web-based training modules offer a real-world perspective on different issues around COVID-19 vaccines. Topics range from routine clinical and vaccine safety information to guidance for on-site clinic vaccination activities and having conversations with vaccine recipients. Each webinar includes self-test practice questions and lists additional resources related to the topic discussed.

The October 19 webinar will focus on the bivalent booster recommendations for children ages 5-11 in lieu of a COCA call. It will be pre-recorded and posted on October 19 at: [COVID-19 Vaccine Webinar Series | CDC](#).

---

## COVID-19 VACCINE RESOURCES

The [Interim Clinical Considerations for Use of COVID-19 Vaccines](#) and FAQs for the pediatric bivalent boosters have been updated.

- <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html>
- <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/faq.html>

Below is a list of resources and upcoming informational activities related to the recommendations. *Some web resources are in process, and expected to be updated on October 13, 2022, or as soon as possible thereafter.*

- [Vaccines.gov](#)
- [CDC COVID-19 booster tool](#)
- Web resources for the public:
  - [Stay Up to Date with Your COVID-19 Vaccines | CDC](#)
  - [COVID-19 Vaccines for People who are Moderately or Severely Immunocompromised | CDC](#)
  - [Overview of COVID-19 Vaccines](#)
  - [Frequently Asked Questions about COVID-19 Vaccination | CDC](#)
  - [COVID-19 Vaccination for Children and Teens with Disabilities | CDC](#)
  - [How Do I Find a COVID-19 Vaccine or Booster?](#)
- Web resources for immunization partners:
  - [Vaccinate with Confidence](#)
  - [Guidance for Vaccinating Older Adults and People with Disabilities: Ensuring Equitable COVID-19 Vaccine Access](#)
  - [Vaccinating Older Adults and People with Disabilities at Vaccination Clinics](#)

## Pfizer Resources

- [Pfizer-BioNTech COVID-19 Vaccine Presentations Wall Chart](#)
- [Fact Sheet For Healthcare Providers- Bivalent Booster Dose For 5-11 Years Of Age](#)

- [Fact Sheet For Recipients And Caregivers- Bivalent Booster Dose For 5-11 Years Of Age](#)
- [Healthcare Provider letter - Bivalent Booster Dose for 5-11 Years of Age](#)

#### **Moderna Resources**

- [Moderna COVID-19 Vaccine Presentations Wall Chart](#)
- [Fact Sheet For Healthcare Providers- Bivalent Booster Dose For 6 Years Of Age and Older](#)
- [Fact Sheet For Recipients And Caregivers- Bivalent Booster Dose For 6 Years Of Age and Older](#)
- [Healthcare Provider letter - Bivalent Booster Dose for 6 Years of Age and Older](#)

---

#### **COVID-19 VACCINE ACCESS AND WASTAGE GUIDANCE**

**Iowa healthcare providers should take every opportunity to vaccinate every eligible person.** As COVID-19 bivalent vaccine supply is more available, focus should shift towards ensuring vaccination of all eligible persons even at the risk of wasting unused doses. The Department supports and encourages efforts to administer vaccine to all eligible individuals. The Department recommends every effort is made to vaccinate eligible persons who present at a vaccine clinic location.

A multi-dose vial may be punctured to vaccinate one or more persons who present for vaccination. Ultimately, the remaining doses of vaccine in the vial may need to be wasted. At this point in Iowa's pandemic response, it is more critical to ensure people who want to be vaccinated with the bivalent COVID-19 vaccine are able to do so.

The CDC COVID-19 Vaccination Program Provider Agreement requires providers to report the number of doses wasted, unused, spoiled, or expired to IRIS. Healthcare providers can use the Adjusting COVID-19 Vaccine Inventory for Wastage instructions to account for wasted doses. IRIS staff are available to help manage IRIS inventory and capture vaccine wastage correctly by calling 800-374-3958.

---

#### **COADMINISTRATION OF COVID-19 VACCINES WITH INFLUENZA AND OTHER VACCINES**

- Providers should offer influenza and COVID-19 vaccines at the same visit, if eligible.
  - This includes adjuvanted or high-dose influenza vaccines; administer in separate limbs.
- With both influenza and SARS-CoV-2 circulating, getting both vaccines is important for prevention of severe disease, hospitalization, and death.
- Getting both vaccines at the same visit increases the chance a person will be up to date with their vaccinations.
- CDC and ACIP [guidance](#) recommends routine administration of all age-appropriate doses of vaccines simultaneously as best practice for people for whom no specific contraindications exist at the time of the healthcare visit.

---

**V-SAFE AFTER VACCINATION HEALTH CHECKER**

V-safe is a smartphone-based tool that uses text messaging and web surveys to provide personalized health check-ins after an individual receives a COVID-19 vaccination. V-safe web pages feature information on how to register and complete a v-safe health check-in (including step-by-instructions with images), troubleshooting, FAQs, and contact information for technical support.

- [V-safe information sheet and poster](#)
- [V-safe after vaccination health checker website](#)
- [V-Safe Print Resources](#)
- [Vaccine Adverse Event Reporting System \(VAERS\)](#)